JAMA Oncology Author Interviews - TopPodcast.com

View Top 200 Chart

Back to Rankings Page

JAMA Oncology Author Interviews — Health & Fitness
JAMA Oncology Author Interviews

Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.

Latest Episodes:

Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in ERBB2-Positive Breast Cancer Jun 24, 2021

Show notes

Interview with Thomas Hatschek, MD, PhD, author of Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial

Efficacy and Safety of Stereotactic Radiosurgery for Brainstem Metastases May 13, 2021

Show notes

Interview with David R. Raleigh, MD, PhD, and William C. Chen, MD, authors of Efficacy and Safety of Stereotactic Radiosurgery for Brainstem Metastases: A Systematic Review and Meta-analysis

Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint–Based Therapy in Patients With Advanced NSCLC Apr 15, 2021

Show notes

Interview with Charu Aggarwal, MD, and Lova Sun, MD, authors of Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor–Based Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

Chronic Toxic Effects Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma Mar 25, 2021

Show notes

Interview with Douglas B. Johnson, MD, author of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma

Anti–PD-1 Immunotherapy in Microsatellite-Stable Tumors With 10 or More Mutations per Megabase Feb 18, 2021

Show notes

Interview with Luc GT Morris, MD MSc, author of Response Rates to Anti–PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase

Virtual Care Across a Tertiary Cancer Center During COVID-19 Jan 07, 2021

Show notes

Interview with Alejandro Berlin, MD, MSc, author of Implementation and Outcomes of Virtual Care Across a Tertiary Cancer Center During COVID-19

Osteonecrosis of the Jaw in Patients Receiving Zoledronic Acid for Bone Metastases Dec 17, 2020

Show notes

Interview with Catherine Van Poznak, MD, author of Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer

Discontinuation of Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia Nov 12, 2020

Show notes

Interview with Ehab Atallah, MD, author of Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial

Association of Measurable Residual Disease With Survival in Patients With Acute Myeloid Leukemia Oct 08, 2020

Show notes

Interview with Farhad Ravandi, MD, author of Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis

Survival and Adjuvant Chemotherapy in Early-Stage NSCLC With vs Without Clinicopathologic Features Sep 17, 2020

Show notes

Interview with Daniel J Boffa, MD, author of Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non–Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features

Related Podcasts